ArticleOncogene2014
DLC1 induces expression of E-cadherin in prostate cancer cells through Rho pathway and suppresses invasion.
Article in Oncogene, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 45 citations in OpenAlex.
- Haplotype GWAS in Colorectal Cancer Patients with a Family History of Gastric or Prostate Cancer.International journal of molecular sciences · 2026Article
- Rho Small GTPase Family in Androgen-Regulated Prostate Cancer Progression and Metastasis.Cancers · 2025Review
- Current landscape of exosomal non-coding RNAs in prostate cancer: Modulators and biomarkers.Non-coding RNA research · 2024Review
- DLC1 promotes mechanotransductive feedback for YAP via RhoGAP-mediated focal adhesion turnover.Journal of cell science · 2024Article
- Deleted in liver cancer 1 suppresses the growth of prostate cancer cells through inhibiting Rho-associated protein kinase pathway.Asian journal of urology · 2023Article
- Evaluation of the causal relationship between smoking and schizophrenia in East Asia.Schizophrenia (Heidelberg, Germany) · 2022Article
- Role of RhoC in cancer cell migration.Cancer cell international · 2021Review
- Mutational drivers of cancer cell migration and invasion.British journal of cancer · 2021Review
- Nuclear DLC1 exerts oncogenic function through association with FOXK1 for cooperative activation of MMP9 expression in melanoma.Oncogene · 2020Article
- The tumor suppressor DLC1 inhibits cancer progression and oncogenic autophagy in hepatocellular carcinoma.Laboratory investigation; a journal of technical methods and pathology · 2018Article
- Cholesterol Esterification Inhibition Suppresses Prostate Cancer Metastasis by Impairing the Wnt/β-catenin Pathway.Molecular cancer research : MCR · 2018Article
- Evidence for critical role of Tie2/Ang1 interaction in metastatic oral cancer.Oncology letters · 2018Article
- An epigenetic signature of adhesion molecules predicts poor prognosis of ovarian cancer patients.Oncotarget · 2017Article
- Arctigenin inhibits prostate tumor cell growthClinical nutrition experimental · 2017Article
- Clinicopathological significance of ROCK1 and PIK3CA expression in nasopharyngeal carcinoma.Experimental and therapeutic medicine · 2017Article
- Deciphering the Molecular and Functional Basis of RHOGAP Family Proteins: A SYSTEMATIC APPROACH TOWARD SELECTIVE INACTIVATION OF RHO FAMILY PROTEINS.The Journal of biological chemistry · 2016Article
- Investigation of the molecular mechanisms underlying metastasis in prostate cancer by gene expression profiling.Experimental and therapeutic medicine · 2016Article
- Intrauterine trophoblast migration: A comparative view of humans and rodents.Cell adhesion & migration · 2016Review
- Proteolytic and non-proteolytic regulation of collective cell invasion: tuning by ECM density and organization.Scientific reports · 2016Article
- MicroRNA-106b promotes colorectal cancer cell migration and invasion by directly targeting DLC1.Journal of experimental & clinical cancer research : CR · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
E-cadherin is a cell-cell adhesion molecule that acts as a suppressor of cancer cell invasion and its expression is downregulated in many advanced, poorly differentiated, human cancers. In this study, we found that the expression of DLC1 (deleted in liver cancer 1) tumor-suppressor gene in metastatic prostate carcinoma (PCA) cells increased the expression of E-cadherin and resulted in an elevated rate of cell-cell aggregation as measured by aggregation assay. DLC1-mediated increase in E-cadherin expression was not dependent on α-catenin, a DLC1-binding protein associated with E-cadherin, and/or cellular density. The increase of E-cadherin expression occurred at mRNA level and relied on DLC1 RhoGAP function, leading to suppression of high level of RhoA-GTP and RhoC-GTP activity in metastatic PCA cells. Application of Rho/ROCK inhibitors produced the same effect as introduction of DLC1. Knocking down of RhoA produced a moderate increase in E-cadherin whereas knocking down of RhoC resulted in a significant increase of E-cadherin. Downregulation of E-cadherin caused by constitutively active RhoA(V14) and RhoC(V14) could not be reversed by expression of DLC1 in DLC1-negative cell line. DLC1-mediated suppression of metastatic PCA cells invasion was comparable with the one associated with ectopic E-cadherin expression, or caused by suppression of Rho pathway either by Rho/ROCK inhibitors, or by shRNA repression. This study demonstrates that DLC1 expression positively regulates E-cadherin and suppresses highly metastatic PCA cell invasion by modulating Rho pathway, which appears as a feasible therapeutic target in cancers with high activity of RhoGTPases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.